Abstracts tagged "Psoriatic arthritis"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: LB08 • ACR Convergence 2025
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Philip Mease¹, Frank Behrens², Alan Kivitz³, Edit Drescher⁴, Piotr Klimiuk⁵, Howard Sofen⁶, Nehad Soloman⁷, Shephard Mpofu⁸, Fredrik Frejd⁹ and Peter Taylor¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ²Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ³Altoona Arthritis and Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, ⁴Vital Medical Center Rheumatology, Veszprém, Hungary, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Medicine/Dermatology, David Geffen UCLA School of Medicine, Los Angeles, California, ⁷Midwestern University Arizona College of Osteopathic Medicine and Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, ⁸ACELYRIN, INC., Agoura Hills, California, ⁹Affibody Medical AB, Solna, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is a chronic, systemic, inflammatory musculoskeletal disease in which dysregulated IL-17A activity plays a pivotal role in disease pathogenesis. Izokibep (IZO) is an…
Abstract Number: LB20 • ACR Convergence 2025
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Désirée van der Heijde¹, Philip Mease², Carle Paul³, Frank Behrens⁴, Laure Gossec⁵, Yuko Kaneko⁶, Lihi Eder⁷, Laura Coates⁸, Andrew Pink⁹, Weiguo Wan¹⁰, Enrique Soriano¹¹, Piotr Leszczyński¹², Jose Scher¹³, Atul Deodhar¹⁴, Chahin Pachai¹⁵, Janice Li¹⁶, Xue Fan¹⁶, Sahar Rabbat¹⁶, Caroline Sardinas¹⁷, Michael Plewinski¹⁸, John Vaile¹⁹ and Joseph Merola²⁰, ¹Leiden University Medical Center, Meerssen, Netherlands, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ³Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse, France, ⁴Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁵Sorbonne Université, AP-HP & EULAR, Paris, France, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁷University of Toronto, Toronto, Ontario, Canada, ⁸University of Oxford, Oxford, United Kingdom, ⁹St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom, ¹⁰Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Department of Internal Medicine and Metabolic Disorders, Poznań University of Medical Sciences, Poznań, Poland, ¹³New York University School of Medicine, New York, New York, ¹⁴Oregon Health & Science University, Portland, Oregon, ¹⁵Bristol Myers Squibb, Princeton, New Jersey, ¹⁶Bristol Myers Squibb, Princeton, ¹⁷Bristol Myers Squibb, garwood, New Jersey, ¹⁸Bristol Myers Squibb, Green Brook Township, New Jersey, ¹⁹Bristol Myers Squibb, Warren, New Jersey, ²⁰UT Southwestern Medical Center, Dallas, Texas
Background/Purpose: Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor being investigated in active PsA in the global, randomized, double-blind, placebo (PBO)-controlled, phase 3…
Abstract Number: 2373 • ACR Convergence 2025
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Rocio Gonzalez Molina¹, BEATRIZ JOVEN², Marta Llanes³, Vanesa Hernandez⁴, Manuel Jose Moreno⁵, Elena Blanco⁶, Carolina Marin⁷, Lourdes Mateo⁸, Meritxell Salles Lizarzaburu⁹, Martina Steiner¹⁰, Laura Nuño¹¹, Antonio Fernández-Nebro¹², raúl Veroz González¹³, ana Urruticoechea-Arana¹⁴, Evelin Cervantes¹⁵, emilio Giner¹⁶, Lola Fernandez de la fuente Burson¹⁷, Alba Erra¹⁸, Oscar Camacho¹⁹, Elisabet Garcia²⁰, Angeles Hernandez²¹, Janire Malave²², Laia Orpinell²³, Inmaculada Ros Vilamajo²⁴, Sonia Castro²⁵, Patricia Lopez Viejo²⁶, Luis Sarabia²⁷, Rosa María García Portales²⁸, Jorge Cabezon²⁹, Puerto Moreno Gil³⁰, Francisco Maceiras³¹, Daniel Pielfort³², Sabela Diaz-Castroverde³³, Manuel Cuervas-mons³³, Jose Pinto-Tasende³⁴, Santiago Muñoz³⁵ and Julio Ramirez³⁶, ¹Hospital Reina Sofía, Murcia, Spain, ²H. Universitario ¹² Octubre, Madrid, Spain, ³H Juan Ramón Jimenez, Huelva, Spain, ⁴Hospital Universitario Canarias, Tenerife, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, El Palmar Murcia, Spain, ⁶Hospital Virgen del Rocio, Sevilla, Spain, ⁷Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁸Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ⁹Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Rheumatology. Hospital de Mérida. Mérida, Spain., Mérida, Spain, ¹⁴Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ¹⁵Hospital Provincial de Pontevedra, Pontevedra, Spain, ¹⁶Hospital Royo Vilanova, Zaragoza, Spain, ¹⁷Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁸Hospital Vall d´Hebron, Barcelona, Spain, ¹⁹Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²⁰Hospital Mollet, Barcelona, Spain, ²¹Hospital Naval, A Coruña, Spain, ²²Hospital Virgen del Puerto, Caceres, Spain, ²³Hospital Universitari Sagrat Cor, Barcelona, Spain, ²⁴Hospital Son Llàtzer, Palma de Mallorca, Spain, ²⁵ALTHAIA Hospital Sant Joan de Deu, Barcelona, Spain, ²⁶Hospital Universitario Getafe, Getafe, Spain, ²⁷Complejo Hospitalario de Jaén, Jaén, Spain, ²⁸HOSP. UNIVERSITARIO VIRGEN DE LA VICTORIA, Malaga, Spain, ²⁹HOSP. PUNTA DE EUROPA, Algeciras, Spain, ³⁰HOSPITAL SAN PEDRO DE ALCANTARA, Caceres, Spain, ³¹HOSPITAL DO MEIXOEIRO, Vigo, Spain, ³²Hospital General Universitario de Toledo, Toledo, Spain, ³³Johnson and Johnson, Madrid, Spain, ³⁴Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ³⁶Clinic Barcelona Hospital Universitari, Barcelona, Catalonia, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease affecting joints, entheses, skin, nails, and spine. While treatment options have expanded, TNF inhibitors (TNFis) remain the…
Abstract Number: 2352 • ACR Convergence 2025
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Martin Rudwaleit¹, Irene E. van der Horst-Bruinsma², Floris A. van Gaalen³, Nigil Haroon⁴, Lianne S. Gensler⁵, Myriam Manente⁶, Chetan Prajapati⁷, Katy White⁷, Atul Deodhar⁸ and Matthew A. Brown⁹, ¹Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ²Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶UCB, Braine-L'Alleud, Belgium, ⁷UCB, Slough, United Kingdom, ⁸Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁹Genomics England, London, United Kingdom
Background/Purpose: Uveitis is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA); incidence varies with SpA type and disease duration.1–3 IL-17 has been implicated…
Abstract Number: 2311 • ACR Convergence 2025
Obstructive Sleep Apnea Syndrome in Patients with Psoriatic Arthritis and Its Relationship with Disease Activity and Comorbidities
Esther Toledano¹, Carolina Cristina Chacón², Cristina Hidalgo Calleja², Belén Miguel², Laura Blanco², Ana Turrión³, Olga Compán⁴, Manuel Martín³, Susana Gómez² and Carlos Montilla², ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ³Rheumatology Service, University Hospital of Salamanca, Salamanca, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain
Background/Purpose: Obstructive sleep apnea syndrome (OSAS) is a chronic respiratory disorder characterized by intermittent upper airway collapse during sleep. This mechanism can trigger systemic inflammation…
Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Philip J. Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Myriam Manente⁴, Luke Peterson⁵, Katy White⁶, Peter Nash⁷ and Lianne S. Gensler⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³UCB, Slough, England, United Kingdom, ⁴UCB, Braine-L'Alleud, Belgium, ⁵UCB, Morrisville, NC, ⁶UCB, Slough, United Kingdom, ⁷School of Medicine, Griffith University, Brisbane, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…
Abstract Number: 1414 • ACR Convergence 2025
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Eugeniu Russu¹, Victor Cazac², Mircea Betiu³, Alesea Nistor³ and Liliana Groppa⁴, ¹"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova, ²Norwalk Hospital, Nuvance Health, Connecticut, ³State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Chisinau, Moldova, ⁴State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops in ~20-30% of psoriasis patients. However, early PsA diagnosis is challenging due to heterogeneous, subtle symptoms and overlap with psoriasis…
Abstract Number: 0591 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Felipe Julio Ramirez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Jérémy Lambert¹², Rajan Bajracharya¹³, Patrik Öhagen¹⁴ and William Tillett¹⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Colombes, France, ¹³UCB, Slough, England, United Kingdom, ¹⁴UCB, Stockholm, Sweden, ¹⁵Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody…
Abstract Number: 0559 • ACR Convergence 2025
Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Javier R Godo¹, Christopher EM Griffiths², Miguel A. González-Gay³, Andreas Clemens⁴, Cynthia Vizcaya⁴, Lara Gómez⁵ and Nehal N Mehta⁶, ¹Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, ²Centre for Dermatology Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK and Department of Dermatology, King's College Hospital NHS Foundation Trust, King's College London, London, United Kingdom, ³Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Farmaceutica, Madrid, Spain, ⁶The George Washington University School of Medicine and Health Sciences, Washington DC
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are associated with increased risk of cardiovascular (CV) disease driven by chronic systemic inflammation, with IL-17A…
Abstract Number: 0532 • ACR Convergence 2025
Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
Antonio Tonutti¹, Saverio D'Amico², Pierandrea Morandini², Cosimo Faeti², Elisa Barone¹, Nicoletta Luciano¹, Victor Savevski² and Carlo Selmi³, ¹Humanitas University, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano, Italy, ³Humanitas University, Milan, Italy
Background/Purpose: Distinguishing seronegative rheumatoid arthritis (RA) from psoriatic arthritis (PsA) sine psoriasis remains challenging, often relying on pathognomonic features (axial involvement, enthesitis) present in only…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…
Abstract Number: 2371 • ACR Convergence 2025
A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis
Raquel Granados¹, Jesús Eduardo Martín Salazar², María Ángeles Puche-Larrubia³, Pedro Ortiz Buitrago⁴, María Dolores López-Montilla⁵, Jerusalén Calvo⁶, Rafaela Ortega-Castro⁷, Montserrat Romero-Gómez⁸, Alejandro Escudero-Contreras⁹, Nuria Barbarroja¹⁰ and Clementina López Medina¹¹, ¹Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain, ²Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁸Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ⁹Reina Sofia University Hospital/Maimonides Institute of Biomedical Research of Córdoba(IMIBIC)/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease requiring individualized treatment strategies. Early identification of patients likely to respond to therapy is essential to…
Abstract Number: 2351 • ACR Convergence 2025
Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Jay Tang¹, Paresh Thakker¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: There is a significant unmet need for clinically informative biomarkers of disease activity and therapeutic response in immune-mediated inflammatory diseases (IMIDs). Tyrosine kinase 2…

1
2
3
…
93
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].